Skip to content
Screener

Dianthus Therapeutics DNTH Clinical Operation Activities — Claseprubart Program Related Expenses

Similar metrics at other companies

NUV
NUVLDiscovery Programs — Direct Expenses Related To Program
$2.8M+31.4%
Rein Therapeutics Inc. logo
RNTXClinical Operation Activities — Research And Development Expense
$1.96M+191%
OnKure Therapeutics, Inc. logo
OKURClinical Research — Direct Program Expense
$6.72M-14.7%
OnKure Therapeutics, Inc. logo
OKURClinical Research — Indirect Program Expense
$474K-9.9%
Delcath Systems logo
DCTHClinical expenses
$2.62M+139%
Arvinas logo
ARVNOther programs — Program-specific external expense
$2.6M+52.9%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.15B+838%
Enterprise value$5.52B+758%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept dnth:ClaseprubartProgramRelatedExpenses.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
License revenue$463$1,163
Research and development expenses:
Claseprubart program-related expenses:
Clinical operation activity costs14,15611,739
CMC activity costs3,7133,811
Preclinical study activity costs3201,041
Total claseprubart program-related expenses18,18916,591
Discovery expenses1,363900

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's clinical operation activities — claseprubart program related expenses?
Dianthus Therapeutics (DNTH) reported clinical operation activities — claseprubart program related expenses of $14.16M in Q1 2026.
What does clinical operation activities — claseprubart program related expenses mean?
This metric represents the direct research and development expenditures specifically allocated to the clinical advancement of the claseprubart therapeutic candidate. It encompasses costs related to clinical trial execution, patient recruitment, and regulatory documentation necessary to progress the asset through clinical development phases. Monitoring these expenses provides insight into the capital intensity and development velocity of the company's lead pipeline assets.

Ask your AI about Dianthus Therapeutics's clinical operation activities — claseprubart program related expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude